logo
  

AVANGRID Backs FY22 Earnings View

AVANGRID, Inc. (AGR), a U.S. arm of Spanish utility Iberdrola S.A. (IBDSF.PK) , said on Thursday that it has reaffirmed its earnings guidance for the full-year. In addition, it added that the company is investing around $15 billion through 2025.

For the fiscal 2022, the company continues to expect EPS and adjusted EPS of $2.20 to $2.38. Analysts, on average, expect the firm to post EPS of $2.34.

Pedro Azagra, CEO of AVANGRID, said: "In the next several years, we plan to strengthen our position with a disciplined investment plan of approximately $15 billion through 2025, $8.1 billion without PNM Resources. Through our Networks business, we are working to modernize the grid and further integrate clean energy into the system…These investments in both the regulated and contracted renewables will generate predictable earnings and cash flow through and beyond our 2022 to 2025 long-term outlook."

AVANGRID has also provided a financial outlook of 6 percent to7 percent income per share and adjusted EPS compound annual growth rate for 2022-2025 including PNM Resources.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT